Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

660 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Progression to hepatitis C virus micro-elimination in people living with HIV in Spain.
Rivero-Juarez A, Tellez F, Mayorga MI, Merino D, Espinosa N, Macias J, Palacios R, Paniagua M, Collado A, Mohamed O, Perez-Stachowski J, Hernandez-Quero J, Fernandez-Fuertes E, Rivero A; Grupo de estudio de Hepatitis virales (HEPAVIR) of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Rivero-Juarez A, et al. Among authors: rivero a. Clin Microbiol Infect. 2020 Oct 31:S1198-743X(20)30654-6. doi: 10.1016/j.cmi.2020.10.023. Online ahead of print. Clin Microbiol Infect. 2020. PMID: 33137514 Free article. No abstract available.
Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C.
Macías J, Mira JA, López-Cortés LF, Santos I, Girón-González JA, González-Serrano M, Merino D, Hernández-Quero J, Rivero A, Merchante N, Trastoy M, Carrillo-Gómez R, Arizcorreta-Yarza A, Gómez-Mateos J, Pineda JA. Macías J, et al. Among authors: rivero a. Antivir Ther. 2006;11(7):839-46. Antivir Ther. 2006. PMID: 17302246
Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.
Pineda JA, García-García JA, Aguilar-Guisado M, Ríos-Villegas MJ, Ruiz-Morales J, Rivero A, del Valle J, Luque R, Rodríguez-Baño J, González-Serrano M, Camacho A, Macías J, Grilo I, Gómez-Mateos JM; Grupo para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Pineda JA, et al. Among authors: rivero a. Hepatology. 2007 Sep;46(3):622-30. doi: 10.1002/hep.21757. Hepatology. 2007. PMID: 17659577
The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection.
Vergara S, Macías J, Rivero A, Gutiérrez-Valencia A, González-Serrano M, Merino D, Ríos MJ, García-García JA, Camacho A, López-Cortés L, Ruiz J, de la Torre J, Viciana P, Pineda JA; Grupo para el Estudio de las Hepatitis Viricas de la SAEI. Vergara S, et al. Among authors: rivero a. Clin Infect Dis. 2007 Oct 15;45(8):969-74. doi: 10.1086/521857. Epub 2007 Sep 11. Clin Infect Dis. 2007. PMID: 17879910
Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Pineda JA, Mira JA, Gil Ide L, Valera-Bestard B, Rivero A, Merino D, Girón-González JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Carrillo-Gómez R, López-Cortés LF, Gómez-Mateos J. Pineda JA, et al. Among authors: rivero a. J Antimicrob Chemother. 2007 Dec;60(6):1347-54. doi: 10.1093/jac/dkm373. Epub 2007 Oct 14. J Antimicrob Chemother. 2007. PMID: 17938129
Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Mira JA, López-Cortés LF, Merino D, Arizcorreta-Yarza A, Rivero A, Collado A, Ríos-Villegas MJ, González-Serrano M, Torres-Tortoso M, Macías J, Valera-Bestard B, Fernández-Fuertes E, Girón-González JA, Lozano F, Pineda JA; Grupo para el Estudio de las Hepatitis Viricas de la Sociedad Andaluza de Enfermedades Infecciosas. Mira JA, et al. Among authors: rivero a. Antivir Ther. 2007;12(8):1225-35. Antivir Ther. 2007. PMID: 18240862
Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up.
Santos J, Palacios R, Lozano F, López M, Gálvez MC, de la Torres J, López-Cortés LF, Ríos MJ, Rivero A; Grupo Andaluz Para el Estudio de las Enfermedades Infecciosas (GAEI). Santos J, et al. Among authors: rivero a. AIDS Res Hum Retroviruses. 2008 Jan;24(1):24-6. doi: 10.1089/aid.2007.0142. AIDS Res Hum Retroviruses. 2008. PMID: 18275344 Free article. Clinical Trial.
Baseline serum low-density lipoprotein cholesterol levels predict response to hepatitis C virus therapy in HIV/hepatitis C virus coinfected patients.
del Valle J, Mira JA, de los Santos I, López-Cortés LF, Merino D, Rivero A, Girón JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Pineda JA. del Valle J, et al. Among authors: rivero a. AIDS. 2008 May 11;22(8):923-30. doi: 10.1097/QAD.0b013e3282ff8ad3. AIDS. 2008. PMID: 18453851
Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
Crespo M, Mira JA, Pineda JA, Van den Eynde E, Ríos-Villegas MJ, Collado A, Girón-González JA, López-Cortés LF, González-Serrano M, Rivero A, Merino D, Esteban JI. Crespo M, et al. Among authors: rivero a. J Antimicrob Chemother. 2008 Oct;62(4):793-6. doi: 10.1093/jac/dkn262. Epub 2008 Jun 21. J Antimicrob Chemother. 2008. PMID: 18567911
660 results